Testing a new immune therapy alone and with another drug for aggressive blood cancers

This trial is testing a new medication called UB-VV400, which is designed to target and fight aggressive B-cell lymphomas—cancers of the immune system—that have come back or stopped responding to previous treatments. Researchers want to find the right dose of UB-VV400 alone and also test whether combining it with a second drug called rapamycin works better. The study will help doctors understand how safe and effective this new treatment approach is for patients who have limited options.

Many patients with aggressive lymphoma run out of treatment options when their cancer comes back or stops responding to standard therapies, especially those who have already tried CAR T-cell therapy. This trial exists because doctors need new ways to help these patients, and early research suggests that this medication might offer hope for people who otherwise have few choices.